(CLR 10-23) A Phase I Pharmacokinetic and Safety Study of Paclitaxel Injection Concentrate for Nano-Dispersion (PICN) Alone and in Combination with Carboplatin in Subjects with Advanced Solid Malignancies
Description: 

There are 2 parts in this study (Part A and Part B) that will be conducted sequentially. Your doctor will be able to tell you which part you are participating in. In Part A, patients will receive PICN (Paclitaxel injection concentrate for nano-dispersion) and the purpose to test the safety of paclitaxel injection concentrate for nano-dispersion (PICN) and see what effects (good or bad) on the patient and there type of cancer, and to find the highest dose of PICN that can be given without causing severe side effects. In part B, patients will receive PICN and carboplatin and the purpose is to test the safety if PICN in combination with carboplatin and see what effects (good or bad) on the patient and there type of cancer, and to find the highest dose of PICN that can be given with carboplatin without causing severe side effects.

Study Number: 

I 187310

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01304303

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.